drugset / Trial / NCT00002956
Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Donor lymphocytes that have been exposed to Epstein-Barr virus may be able to help the body kill cancers associated with this virus. PURPOSE: Phase I trial to study the effectiveness of Epstein-Barr virus-specific T cells derived from matched donors in organ transplant patients with lymphoproliferative diseases associated with Epstein-Barr virus.
Timeline
- Start
- 1996-11
- Primary completion
- 2002-02
- Completion
- 2002-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes | Cell therapy | — | — |